ODАM PАPILLOMА VIRUSI VА OGʼIZ-XАLQUM SАRАTONI: JIHАTLАRIGА KLINIK-EPIDEMIOLOGIK VА PROGNOSTIK NАZАRLАR (АDАBIYOTLАR SHАRHI)
##article.subject##:
оғиз-халқум саратони; инсон папиллома вируси; ОПВ-ассоцияланган рак; эпидемиология; канцерогенез; p16; диагностика; прогноз; персоналлаштирилган даволаш##article.abstract##
Maqsad: Сўнгги ўн йилликларда оғиз-халқум саратони эпидемиологик профилининг сезиларли даражада ўзгариши билан характерланиб, инсон папиллома вируси (ОПВ) билан боғлиқ шакллар улушининг ортиши кузатилмоқда. Ҳозирги кунда ОПВ-позитив оғиз-халқум саратони бош ва бўйин соҳаси ўсмаларининг мустақил клиник-биологик подтипи сифатида қаралиб, у хавф омиллари, морфологик хусусиятлари, клиник кечиши ва прогнози билан ОПВ-негатив ўсмалардан фарқ қилади. Ушбу адабиётлар шарҳида ОПВ-ассоцияланган оғиз-халқум саратони тарқалиши, вирус биологияси ва ОПВ-индуцирланган канцерогенез механизмлари, клинико-морфологик хусусиятлар ҳамда диагностика ёндашувларига оид замонавий маълумотлар умумлаштирилган. ОПВ-статуснинг прогностик аҳамияти, вирус генотипи, вирус юкламаси ва ОПВнинг физик статусининг клиник натижаларни шакллантиришдаги ўрнига алоҳида эътибор қаратилган, шунингдек персоналлаштирилган даволаш ва терапияни деэскалация қилишнинг замонавий концепциялари ёритилган. ОПВнинг клиник, морфологик ва молекуляр хусусиятларини интеграция қилиш беморларнинг прогностик стратификациясини чуқурлаштириш ва даволаш тактикасини оптималлаштириш имконини бериши кўрсатилган. ОПВ-ассоцияланган оғиз-халқум саратонининг эпидемиологик ҳамда клинико-прогностик хусусиятларини аниқлаш мақсадида минтақавий йўналтирилган тадқиқотлар ўтказиш зарурлиги таъкидланган.
Библиографические ссылки
Лопатин А.С. Эндоскопия верхних дыхательных путей. Москва: ГЭОТАР-Медиа; 2017. С. 198–223.
Ang K.K., Harris J., Wheeler R., et al. HPV and survival of patients with OPSCC. N Engl J Med. 2010;363:24–35.
Ang K.K., Harris J., Wheeler R., et al. Human papillomavirus and survival of patients with oropharyngeal cancer. New England Journal of Medicine. 2010;363:24–35.
Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., zur Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401(1):70–79.
Boscolo-Rizzo P., Pawlita M., Holzinger D. From HPV-positive towards HPV-driven oropharyngeal squamous cell carcinomas. Cancer Treatment Reviews. 2016;42:24–29.
Branstetter B.F. IV, Blodgett T.M., Zimmer L.A., et al. Head and neck malignancy: PET/CT imaging. Radiology. 2005;237(2):404–414.
Castellsagué X., Alemany L., Quer M., et al. HPV involvement in head and neck cancers: comprehensive assessment. The Lancet Oncology. 2016;17(7):982–992.
Chaturvedi A.K., Engels E.A., Pfeiffer R.M., et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. Journal of Clinical Oncology. 2011;29(32):4294–4301.
College of American Pathologists, ASCO, AMP. Human papillomavirus testing in head and neck carcinomas. Archives of Pathology & Laboratory Medicine. 2018;142(5):559–597.
D’Souza G., Kreimer A.R., Viscidi R., et al. Case-control study of HPV and OPSCC. N Engl J Med. 2007;356:1944–1956.
Dahlgren L., Mellin H., Wangsa D., et al. Comparative genomic profiling of HPV-positive OPSCC. International Journal of Cancer. 2003;107(5):847–852.
Doorbar J., Quint W., Banks L., Bravo I.G., Stoler M., Broker T.R., Stanley M.A. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–F70.
Dyson N., Howley P.M., Münger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science. 1989;243(4893):934–937.
El-Naggar A.K., Chan J.K.C., Grandis J.R., Takata T., Slootweg P.J. (eds.) WHO Classification of Head and Neck Tumours. 4th ed. Lyon: IARC; 2017. p. 119–141.
Fakhry C., Westra W.H., Li S., et al. Improved survival of patients with HPV-positive OPSCC. Journal of the National Cancer Institute. 2008;100(4):261–269.
Fakhry C., Zhang Q., Nguyen-Tan P.F., et al. Human papillomavirus and response to therapy. Journal of Clinical Oncology. 2014;32(30):3365–3373.
Gillison M.L., Chaturvedi A.K., Anderson W.F., Fakhry C. Epidemiology of human papillomavirus–positive head and neck squamous cell carcinoma. J Clin Oncol. 2015;33(29):3235–3242.
Gillison M.L., Koch W.M., Capone R.B., et al. Evidence for a causal association between HPV and a subset of head and neck cancers. Journal of the National Cancer Institute. 2000;92(9):709–720.
Gillison M.L., Koch W.M., Capone R.B., Spafford M., Westra W.H., Wu L., Zahurak M.L., Daniel R.W., Viglione M., Symer D.E., Shah K.V., Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. Journal of the National Cancer Institute. 2000;92(9):709–720.
Gillison M.L., Zhang Q., Jordan R., et al. Tobacco smoking and increased risk of death in HPV-positive OPSCC. Journal of Clinical Oncology. 2012;30(17):2102–2111.
Goldenberg D., Begum S., Westra W.H., et al. Cystic lymph node metastasis in HPV-related OPSCC. Archives of Otolaryngology – Head & Neck Surgery. 2008;134(6):654–660.
Hauck F., Domschke C., et al. Recommendations for HPV testing. Virchows Archiv. 2014;465(3):251–261.
Holzinger D., et al. Biomarkers and prognosis in HPV-driven OPSCC. Journal of Clinical Oncology. 2012;30(26):3075–3083.
Holzinger D., et al. Viral transcription and prognosis in OPSCC. Clinical Cancer Research. 2012;18(18):4986–4997.
Holzinger D., Flechtenmacher C., Henfling N., et al. HPV DNA load and survival. Journal of Clinical Oncology. 2012;30(26):3075–3083.
Huang S.H., Xu W., Waldron J., et al. Refining prognosis in HPV-related OPSCC. Journal of Clinical Oncology. 2015;33(8):836–845.
Kreimer A.R., Clifford G.M., Boyle P., Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiology, Biomarkers & Prevention. 2005;14(2):467–475.
Lechner M., Liu J., Masterson L., Fenton T.R. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nature Reviews Clinical Oncology. 2022;19(5):306–327.
Lewis J.S. Jr. p16 Immunohistochemistry as a surrogate marker of HPV. Head & Neck Pathology. 2012;6(Suppl 1):S75–S82.
Lewis J.S. Jr., Beadle B., Bishop J.A., Chernock R.D., Colasacco C., Lacchetti C., et al. Human papillomavirus testing in head and neck carcinomas: guideline. Archives of Pathology & Laboratory Medicine. 2018;142(5):559–597.
Lydiatt W.M., Patel S.G., O’Sullivan B., Brandwein M.S., Ridge J.A., Migliacci J.C., Loomis A.M., Shah J.P. Head and neck cancers—major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer Journal for Clinicians. 2017;67(2):122–137.
Mantovani F., Banks L. The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene. 2001;20(54):7874–7887.
Marur S., Li S., Cmelak A.J., et al. E1308 trial. Journal of Clinical Oncology. 2017;35(5):490–497.
Masterson L., Moualed D., Masood A., et al. De-escalation treatment protocols. Oral Oncology. 2014;50(5):354–360.
Mehanna H., Beech T., Nicholson T., El-Hariry I., McConkey C., Paleri V., Roberts S. Prevalence of human papillomavirus in oropharyngeal and non-oropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region. The Lancet Oncology. 2013;14(7):622–629.
Mehanna H., Wong W.L., McConkey C.C., et al. PET-CT surveillance versus neck dissection. New England Journal of Medicine. 2016;374:1444–1454.
Mellin H., Dahlgren L., Munck-Wikland E., et al. Human papillomavirus load in OPSCC. International Journal of Cancer. 2002;102(2):152–158.
Mirabello L., Clarke M.A., Nelson C.W., Dean M., Wentzensen N., Yeager M., et al. The intersection of HPV epidemiology, genomics and mechanistic studies of HPV-mediated carcinogenesis. Viruses. 2018;10(2):80.
Mirghani H., Amen F., Moreau F., et al. Do high-risk human papillomaviruses cause all oropharyngeal squamous cell carcinomas? Cancer Treatment Reviews. 2015;41(6):480–486.
Mirghani H., Blanchard P. Treatment de-escalation for HPV-driven OPSCC. Clinical and Translational Radiation Oncology. 2018;8:4–11.
Moody C.A., Laimins L.A. Human papillomavirus oncoproteins: pathways to transformation. Nature Reviews Cancer. 2010;10(8):550–560.
Münger K., Baldwin A., Edwards K.M., Hayakawa H., Nguyen C.L., Owens M., Grace M., Huh K. Mechanisms of human papillomavirus-induced oncogenesis. Journal of Virology. 2004;78(21):11451–11460.
Ndon S., et al. HPV-associated oropharyngeal cancer: global patterns. Cancers (Basel). 2023;15(16):4080.
Ng S.H., Yen T.C., Liao C.T., et al. 18F-FDG PET and CT/MRI in staging of head and neck cancer. Journal of Nuclear Medicine. 2005;46(12):1902–1908.
Nulton T.J., Kim N.K., DiNardo L.J., et al. HPV integration and its implications in OPSCC. Journal of Virology. 2017;91(4):e02056-16.
O’Sullivan B., Huang S.H., Perez-Ordonez B., et al. Outcomes of HPV-related OPSCC. Journal of Clinical Oncology. 2012;30(19):2109–2116.
O’Sullivan B., Huang S.H., Siu L.L., et al. Deintensification candidate subgroups. Journal of Clinical Oncology. 2013;31(5):543–550.
O’Sullivan B., Huang S.H., Su J., Garden A.S., Sturgis E.M., Dahlstrom K., Lee N., Riaz N., Pei X., Koyfman S.A., Adelstein D., Rosenthal D.I., Ang K.K. Development and validation of a staging system for HPV-related oropharyngeal cancer by the International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S). Journal of Clinical Oncology. 2016;34(36):4350–4357.
Parfenov M., Pedamallu C.S., Gehlenborg N., et al. Characterization of HPV and host genome interactions in primary head and neck cancers. Genome Research. 2014;24(4):646–657.
Podvinec M., Steiner W., Ambrosch P., Pfister D.G. Diagnostic approaches to oropharyngeal cancer. Head & Neck. 2012;34(9):1202–1210.
Poeta M.L., Manola J., Goldwasser M.A., et al. TP53 mutations and survival. New England Journal of Medicine. 2007;357:2552–2561.
Pytynia K.B., Dahlstrom K.R., Sturgis E.M. Epidemiology of HPV-associated oropharyngeal cancer. Oral Oncology. 2014;50(5):380–386.
Reuschenbach M., Kansy K., Garbe K., et al. Lack of evidence of HPV DNA integration in OPSCC associated with favorable outcome. International Journal of Cancer. 2015;137(6):1357–1365.
Rietbergen M.M., Brakenhoff R.H., Bloemena E., et al. Molecular characterization of HPV-positive OPSCC. International Journal of Cancer. 2013;132(10):2367–2375.
Rumgay H., Colombet M., Mery L., et al. Global incidence of lip, oral cavity and pharyngeal cancers by subsite in 2022. CA: A Cancer Journal for Clinicians. 2026;76(1).
Sano T., Oyama T., Kashiwabara K., et al. Expression status of p16 protein is associated with human papillomavirus oncogenic potential. Pathology International. 1998;48(8):580–585.
Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 1990;63(6):1129–1136.
Schmitt M., Dalstein V., Waterboer T., et al. HPV RNA detection in OPSCC. International Journal of Cancer. 2011;128(4):832–838.
Seiwert T.Y., Foster C.C., Blair E.A., et al. De-escalated chemoradiation therapy. Journal of Clinical Oncology. 2019;37(22):1909–1918.
Sinha P., Thorstad W.T., Nussenbaum B., et al. Distant metastases in HPV-positive OPSCC. Head & Neck. 2012;34(6):742–747.
Snietura M., Jaworska M., Pigłowski W., et al. Viral load and physical status of HPV16 in OPSCC. Head & Neck. 2011;33(10):1439–1447.
Syrjänen S. HPV infections and tonsillar carcinoma. Journal of Clinical Pathology. 2004;57(5):449–455.
Tan Y.J., et al. Prevalence of HPV-associated OPSCC: meta-analysis. Acta Med Marisiensis. 2023;69(2):77–92.
Tan Y.J., et al. Prevalence of human papillomavirus-associated oropharyngeal squamous cell carcinoma: meta-analysis with method-dependent estimates. Acta Medica Marisiensis. 2023;69(2):77–92.
Ukpo O.C., Flanagan J.J., Ma X.J., et al. High-risk HPV RNA in situ hybridization assay. American Journal of Surgical Pathology. 2011;35(5):657–663.
Weinstein G.S., O’Malley B.W. Jr. Transoral robotic surgery. Annals of Otology, Rhinology & Laryngology. 2007;116(1):19–23.
Wentzensen N., Vinokurova S., von Knebel Doeberitz M. Systematic review of genomic integration sites of human papillomavirus genomes. Cancer Research. 2004;64(11):3878–3884.
Westra W.H. The morphologic profile of HPV-related head and neck SCC. Head & Neck Pathology. 2009;3(1):1–8.
